All Sarepta articles
-
OpinionRegulatory tightropes
When lobbying and marketing clash with scientific evidence, regulators walk a fine line
-
Business
FDA’s first Duchenne drug approval reveals schism
Oligonucleotide drug reaches market amid pressure from patient families and strife over ‘patient-focused drug development’ at the regulator
